查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712508

全球人體肝臟模型市場 - 2025-2033

Global Human Liver Models Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球人體肝臟模型市場規模達 13.7 億美元，預計到 2033 年將達到 37.6 億美元，在 2025-2033 年預測期內的複合年成長率為 12.3%。

人體肝臟模型是一種先進的結構，旨在模仿人體肝臟的生理和功能屬性。這些模型主要用於研究藥物毒性、肝臟疾病和肝臟解剖的複雜空間動態。複雜的人類肝臟模型可以以多種形式存在，例如類器官、3D 生物列印組織和肝臟晶片系統，所有這些模型都致力於從分子水平及更高水平複製人類肝臟生理學。

市場動態：

駕駛員和約束裝置

肝病盛行率不斷上升

肝病盛行率的不斷上升是全球人體肝臟模型市場擴張的主要動力。發病率的上升迫切需要先進的研究工具，以提高我們對肝功能、疾病過程和藥物交互作用的了解。

根據 2022 年 3 月《BMC 內分泌疾病》研究出版物，包括非酒精性脂肪肝病 (NAFLD)、病毒性肝炎、肝硬化和肝癌在內的慢性肝病的全球盛行率正在顯著增加。例如，NAFLD已成為西方國家最常見的慢性肝病，影響全球約25％的人口。

此外，主要參與者的策略（例如合作夥伴關係、協作、宣傳計劃和創新產品發布）將推動該市場的成長。例如，2024年2月，合作開發用於藥物毒性篩選的肝類器官是一項重要舉措，旨在提高藥物開發過程中新藥的安全性和有效性。該計畫由辛辛那提兒童醫院的 CuSTOM 加速器實驗室牽頭，是丹納赫集團「Beacons」計畫的一部分，專注於利用人類肝臟類器官作為臨床前測試工具的潛力。

同樣，2023 年 2 月，CN Bio 推出了 Physio Mimix 單一器官高通量 (HT) 系統，旨在提高預測性人體肝臟模型在藥物發現中的使用。這項創新系統解決了阻礙這些模型廣泛應用的現有挑戰，使研究人員能夠進行更大規模的比較研究，以評估開發過程早期階段候選藥物的功效、性質和安全性。

人體肝臟模型成本高昂

全球人體肝臟模型市場面臨的主要挑戰之一是開發和維護先進模型的高成本。 3D 生物列印、類器官和器官晶片系統等技術處於創新的前沿，但需要複雜的基礎設施和專門的設備。這些平台不僅採購成本高昂，而且操作和維護成本也高昂，涉及先進的材料、消耗品和高精度。這使得許多新興市場的小型研究機構、新創公司和設施在經濟上無法獲得這些資金。

此外，取得和使用人類來源的細胞（尤其是原代人類肝細胞）的成本非常高。由於道德限制、捐贈者有限以及嚴格的品質控制標準，這些細胞很難獲得。維持其在培養中的生存力和功能會增加進一步的費用，因為它需要豐富的培養基、生長因子和嚴格控制的環境條件。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的程式碼片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 肝病盛行率不斷上升
      • 器官晶片技術與先進3D生物列印技術的發展
    • 限制
      • 人體肝臟模型成本高昂
      • 專業技能人才短缺
    • 機會
      • 虛擬臨床試驗的擴展
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • 最新進展與突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：人體肝臟模型市場（依產品類型）

  • 2D模型
  • 3D模型
    • 肝臟晶片
    • 肝臟類器官
    • 球體
    • 3D生物列印

第6章：人體肝臟模型市場（依應用）

  • ADME研究
  • 藥物研發
  • 毒理學測試
  • 疾病模型
  • 其他

第7章：人體肝臟模型市場（以最終用戶分類）

  • 學術及研究機構
  • 製藥和生物技術公司
  • 合約研究組織

第8章：人體肝臟模型市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Corning Incorporated
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • BioIVT LLC
  • Emulate Inc.
  • InSphero
  • Organovo Holdings Inc.
  • MIMETAS BV
  • CN Bio Innovations Ltd
  • CELLINK
  • Visikol, Inc.
  • Cyprotex PLC

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: BT5842

The global human liver models market reached US$ 1.37 billion in 2024 and is expected to reach US$ 3.76 billion by 2033, growing at a CAGR of 12.3% during the forecast period of 2025-2033.

A human liver model is an advanced construct designed to imitate the physiological and functional attributes of the human liver. These models are mainly utilized for investigating drug toxicity, liver diseases, and the intricate spatial dynamics of liver anatomy. Sophisticated human liver models can exist in various formats, such as organoids, 3D bioprinted tissues, and liver-on-a-chip systems, all striving to replicate human liver physiology from the molecular level and beyond.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Liver Diseases

The growing prevalence of liver diseases is a key driver behind the expansion of the global human liver models market. This rising incidence generates an urgent need for sophisticated research tools that can improve our understanding of liver function, disease processes, and drug interactions.

According to a BMC Endocrine Disorders research publication in March 2022, the global prevalence of chronic liver conditions, including non-alcoholic fatty liver disease (NAFLD), viral hepatitis, cirrhosis, and liver cancer, is increasing significantly. For example, NAFLD has emerged as the most prevalent chronic liver disorder in Western countries, affecting roughly 25% of the global population.

Furthermore, key players' strategies, such as partnerships & collaborations, awareness programs, and innovative product launches, would drive this market growth. For instance, in February 2024, the collaboration to develop liver organoids for drug toxicity screening is a significant initiative aimed at improving the safety and efficacy of new medications during the drug development process. This project, led by the CuSTOM Accelerator Lab at Cincinnati Children's Hospital, is part of Danaher Corporation's "Beacons" program and focuses on harnessing the potential of human liver organoids as a tool for preclinical testing.

Similarly, in February 2023, CN Bio introduced the Physio Mimix Single-organ Higher Throughput (HT) System, aimed at improving the use of predictive human liver models in drug discovery. This innovative system tackles existing challenges that hinder the widespread adoption of these models, allowing researchers to perform larger-scale comparative studies to evaluate the efficacy, disposition, and safety of drug candidates at earlier stages in the development process.

High Costs of Human Liver Models

One of the primary challenges facing the global human liver models market is the high cost associated with developing and maintaining advanced models. Technologies such as 3D bioprinting, organoids, and organ-on-a-chip systems are at the forefront of innovation but require sophisticated infrastructure and specialized equipment. These platforms are not only expensive to procure but also to operate and maintain, involving advanced materials, consumables, and a high degree of precision. This makes them financially inaccessible for many smaller research institutions, startups, and facilities in emerging markets.

In addition, the cost of sourcing and using human-derived cells, particularly primary human hepatocytes, is remarkably high. These cells are difficult to obtain due to ethical constraints, limited donor availability, and strict quality control standards. Maintaining their viability and function in culture adds further expenses, as it requires enriched media, growth factors, and tightly regulated environmental conditions.

Segment Analysis

The global human liver models market is segmented based on product type, application, end-user, and region.

Product Type:

The 3D models segment in product type is expected to dominate the global human liver models market with the highest market share

Conventional 2D cell cultures, which frequently do not accurately mimic the intricate architecture and microenvironment of human tissues, 3D liver models offer a more authentic representation of in vivo conditions. These models integrate various cell types and structural elements that are crucial for effectively studying liver function and drug responses. Recent developments in 3D bioprinting methods have enhanced the viability and functionality of liver cells in these models. For instance, researchers have effectively printed liver tissues that incorporate vascular structures, facilitating improved delivery of nutrients and oxygen, which is essential for sustaining cell health and function over extended periods.

Moreover, key players in the industry are more focused on the ongoing research studies on liver cells and investments that would propel this segment's growth in the market. For instance, in June 2024, Mini liver models, particularly the development of 3D liver spheroids, are set to improve the effectiveness of drug testing significantly. Researchers at King's College London (KCL) have developed a laboratory-grown Mini liver model that integrates liver cells with a synthetic nano scaffold. This novel approach enables the mini liver to more accurately replicate the structure and function of the human liver compared to conventional 2D cell culture models.

Similarly, in April 2024, Bayland Capital and CN Innovations Holdings Ltd, the founding shareholders, are set to invest $10 million and $5.5 million, respectively. This funding will support the expansion of product development and scaling efforts within the organization to meet the growing demand for Organ-on-a-Chip (OOC) solutions. These factors have solidified the segment's position in the global human liver models market.

Geographical Analysis

North America is expected to hold a significant position in the global human liver models market with the highest market share

The increasing prevalence of liver diseases, including non-alcoholic fatty liver disease (NAFLD), hepatitis, cirrhosis, and liver cancer, is a major factor driving the growth of the human liver model market. According to the American Liver Foundation, in September 2023, around 4.5 million adults in the U.S. were affected by liver disease. This rising incidence underscores the urgent need for advanced human liver models that can offer deeper insights into liver function and disease mechanisms, ultimately enhancing the drug discovery process.

Advancements in 3D bioprinting and organ-on-a-chip technologies have greatly enhanced the precision and effectiveness of human liver models. These innovations enable researchers to develop models that are more physiologically relevant and accurately replicate human liver conditions. Moreover, in this region, key players' strategies such as partnerships & collaboration, well-advanced healthcare infrastructure, R&D activities, government initiatives & regulatory bodies' support are driving this market growth.

For instance, in January 2024, CN Bio and Altis Biosystems entered into a strategic partnership to create a next-generation human Gut/Liver in vitro model aimed at improving ADME (Absorption, Distribution, Metabolism, and Excretion) studies. This collaboration combines Altis' RepliGut Planar-Jejunum model with CN Bio's PhysioMimix Liver-on-a-Chip, resulting in a comprehensive microphysiological system (MPS) that simulates inter-organ communication and accurately reflects the oral drug administration process.

Additionally, in September 2023, UC Davis Health introduced a new liver transplant program, representing a significant advancement in its transplant services. This program is set to resume operations after being temporarily closed, with plans to begin accepting patients in the spring of 2023. Thus, the above factors are consolidating the region's position as a dominant force in the global human liver models market.

Competitive Landscape

The major global players in the human liver models market include Corning Incorporated, BioIVT LLC, Emulate Inc., InSphero, Organovo Holdings Inc., MIMETAS B.V., CN Bio Innovations Ltd, CELLINK, Visikol, Inc., and Cyprotex PLC, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global human liver models market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Liver Diseases
      • 3.1.1.2. Growth of Organ-on-a-Chip Technology and Advanced 3D Bioprinting
    • 3.1.2. Restraints
      • 3.1.2.1. High Costs of Human Liver Models
      • 3.1.2.2. Shortage of Skilled Professionals
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion of Virtual Clinical Trials
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics
  • 4.12. Key Opinion Leaders

5. Human Liver Models Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. 2D Models*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. 3D Models
    • 5.3.1. Liver-on-a-Chip
    • 5.3.2. Liver Organoids
    • 5.3.3. Spheroids
    • 5.3.4. 3D Bioprinting

6. Human Liver Models Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. ADME Studies*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Drug Discovery
  • 6.4. Toxicology Testing
  • 6.5. Disease Modelling
  • 6.6. Others

7. Human Liver Models Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Academic & Research Institutes*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Pharmaceutical & Biotechnology Companies
  • 7.4. Contract Research Organizations

8. Human Liver Models Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Corning Incorporated*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. BioIVT LLC
  • 10.3. Emulate Inc.
  • 10.4. InSphero
  • 10.5. Organovo Holdings Inc.
  • 10.6. MIMETAS B.V.
  • 10.7. CN Bio Innovations Ltd
  • 10.8. CELLINK
  • 10.9. Visikol, Inc.
  • 10.10. Cyprotex PLC

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us